Wednesday, July 8, 2026

pharma · MAC Lung Disease · Mycobacterium Abscessus Infection · ANTX

AN2 Therapeutics

AN2 Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Menlo Park, USA HQ
2019 Founded
35 Employees
Public company Type
ANTX · NYSE Ticker
Company details
Status
Public
HQ
Menlo Park, USA
Founded
2019
Employees
35
Programs
6
Drugs
2
Patents
0
Intelligence · Clinical Programs

AN2 Therapeutics projects

4 ClinicalTrials.gov programs sponsored by AN2 Therapeutics.

AN2 Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AN2-502998

    AN2 Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  2. Epetraborole

    AN2 Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  3. Epetraborole

    AN2 Therapeutics

    Renal Insufficiency

    phase 1 small molecule completed

    1 trial
  4. Epetraborole and matching placebo

    AN2 Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does AN2 Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.